Katie Anderson

Katie brings nearly two decades of editorial experience in business-to-business media. After earning her master’s degree in journalism, she began her career at the personal care R&D trade journal Cosmetics & Toiletries. There, she thrived on the constant flow of knowledge gained from interviewing chemists, regulatory experts, formulators and testing professionals in the field.

After nearly eight years with Cosmetics & Toiletries, Katie pursued her passion for skin physiology and ingredient science as Managing Editor of the professional esthetics brand Skin Inc. That same year, she also took on the role of Conference Director for Face and Body, where she developed and managed the event’s educational programming.

Following an acquisition, Katie was promoted to Editor-in-Chief of five professional media brands: Nailpro, Skin Inc., Beauty Launchpad, Medical Esthetics, and WellSpa 360.

Throughout her 19-year editorial career, Katie has held a variety of roles, but her passion has always been scientific editorial. She is the recipient of a bronze Folio Eddie Award for a single science article. She has frequently contributed her expertise as a guest speaker on industry podcasts, webcasts, conferences and video interviews. A lifelong learner, she enjoys the challenge of translating complex technical content into material that is both accurate and accessible.

Connect with Katie on LinkedIn: https://www.linkedin.com/in/katieanderson121/

ARTICLES BY KATIE ANDERSON

Innovation, Growth (and Happiness) Projected for Pharma
11/10/2025

Not only is investment increasing in pharma, but innovation is propelling growth in multiple drug segments, and the people supporting this growth and innovation remain happy.
Shaping The Future Of GLP-1 Quality
11/4/2025

Three experts—Doug Bakan (CTO of Kailera), Hyung Heon Kim (CEO of MetaVia) and Deepa Nagpal (Founder of SygnifyQ)—joined us on Oct. 15, 2025, to explore this topic, find out the most common quality failures, learn what innovation is occurring and find out what business decisions can help support both quality and quantity.
ISPE Awards 8 Innovative Pharma Facilities
10/31/2025

The Facility of the Year Awards (FOYA) celebrates 20 years of innovation and excellence in 2025, and I had the pleasure of joining the celebration at the 2025 ISPE FOYA Banquet and Awards Celebration on Oct. 26, 2025.
9 Drugs Granted Fast Track By FDA's Voucher Program
10/23/2025

With targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
Leaders In The Excipient Market: Region And Type
10/21/2025

Though North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
3 [Potential] Solutions To A More Resilient Supply Chain
10/16/2025

In her opening presentation, Harney noted that there were 98 drug shortages in 2024, 40 medicines in shortage for over three years, and the average duration of a shortage has increased from three years to four years.
Extreme Weather Is Testing Pharma's Resilience — Is It Ready?
10/14/2025

It may sound like a stretch, but researchers from Harvard University showed how a disproportionate amount of pharmaceutical manufacturers are in areas of climate-driven extreme weather events. Is the pharmaceutical industry currently set up to withstand them?
Eco-Friendly HBL: Cheaper, Cleaner, And Ready For Pharma
10/6/2025

Researchers at the University of Maine may have found a way to do two out of three by developing a new method of producing (S)-3-hydroxy-γ-butyrolactone (HBL) for statins, HIV inhibitors and antibiotics that can lower their production cost with an added benefit of reducing their carbon footprint.
Roll Call In The Oral GLP-1 Race
9/26/2025

The market for GLP-1 agonists is booming and expected to only get bigger. As rates for obesity and cardiovascular disease increase, so too does the demand for GLP-1 drugs.
Pfizer Strengthens Obesity Foothold With Metsera Acquisition
9/22/2025

After discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.